HTR1A and synovial sarcoma: Triptans (5-HT1B and 5-HT1D agonists) and ditans (5-hydroxytryptamine-1F agonists), indicated for acute treatment of migraine, have been evaluated for SS, but the mechanism by which this might occur is unclear, as these selective agonists do not bind to 5-HT1A or 5-HT2A receptors (12).